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Abstract The amino acid sequences in the amyloido-
genic region (amino acids 108–144) of several mammalian
prion proteins were compared and variations were found to
occur at residues 109 (M or L), 112 (M or V), 129 (M, V,
or L), 135 (N or S), 138 (M, L, or I), 139 (M or I), and 143
(N or S). Using the bovine PrP peptide (residues 108–144
based on the numbering of the human prion protein
sequence) as a control peptide, several peptides with one
amino acid differing from that of the bovine PrP peptide at
residues 109, 112, 135, 138, 139, or 143 and several
mammalian PrP peptides were synthesized, and the effects
of these amino acid substitutions on the amyloidogenic
properties of these peptides were compared and discussed
on the basis of the chemical and structural properties of
amino acids. Our results showed that the V112M substi-
tution accelerated nucleation of amyloidogenesis, while the
N143S and I139M substitutions retarded nucleation. These
effects tended to cancel each other out when two substi-
tutions with opposite effects were present on the same
peptide. Moreover, acceleration or inhibition of nucleation
was not necessarily correlated with effect on seeding effi-
ciency. Using amyloid fibrils prepared from the bovine PrP
peptide as seeds, the seeding efficiency for the monomer
peptides with the M129L, S135N, N143S, or I139M
substitution was decreased compared to that for bPrP
peptide. Of all the mammalian peptides used in this study,
the dog, mule deer, and pig PrP peptides had the lowest
seeding efficiencies.
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Introduction
Prion diseases are fatal transmissible neurodegenerative
diseases affecting various mammals, including the sheep,
goat, cattle, human, mule deer, elk, cat, and mink
(Chesebro 2003; Prusiner 1998; Aguzzi and Polymenidou
2004; Collinge 2001; Palmer and Collinge 1997; Imran and
Mahmood 2011). In 1982, Prusiner and his colleagues
(Prusiner et al. (1982), Prusiner (1982) and Bolton et al.
(1982)) purified the scrapie agent and coined a new term
‘‘prion’’ to describe the proteinaceous properties of the
infectious material. A few years later, the gene encoding
the prion protein was cloned (Oesch et al. 1985; Basler
et al. 1986) and prion protein was found to be constitu-
tively expressed on the cell surface (Stahl et al. 1987).
However, in addition to the cellular form, denoted PrPC,
the same protein can exist as another isoform, denoted
PrPSc, which is the main component of the infectious prion
and the culprit of prion disease transmission (Basler et al.
1986). Administration of prion by the intracerebral, intra-
peritoneal, intravenous, subcutaneous, intraocular, intra-
spinal, or oral route transmits the disease from one animal
to another and hence prion diseases are called transmissible
spongiform encephalopathies (TSEs). Transmission within
the same species is quite efficient, while transmission from
one species to another is very much less. The transmission
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barrier is reflected in a prolonged incubation time, and
repeated passages are often required for prion ‘‘adaption’’
in a new species (Kimberlin and Walker 1978). The so-
called ‘‘species barrier’’ in prion transmission is an
important and unsolved issue in prion studies.
The structural conversion from the normal cellular form,
PrPC, to the disease-causing form, PrPSc, is the key event in
prion formation. PrPSc is a special form of protein aggregate
that is rich in cross-b structure called amyloid. Although the
structure of PrPSc remains elusive due to its aggregation nat-
ure, synthetic prion peptides consisting of residues 106–126,
127–143, 106–147, 90–145, 171–193 (helix 2), or 199–226
(helix 3) are able to form amyloid fibrils in vitro (Tagliavini
et al. 1993; Zhang et al. 1995; Kuwata et al. 2003; Yamaguchi
et al. 2008; Walsh et al. 2009; Lin et al. 2010). The amyloid
formation process might be explained by a nucleation-
dependent polymerization model (Fig. 1), in which there is a
long lag phase during which seeds (nuclei) are formed (Jarrett
and Lansbury 1993; Caughey et al. 2009; Aguzzi and Poly-
menidou 2004; Serio et al. 2000; Harper and Lansbury 1997).
Prion is the seed that initiates amyloid propagation in prion
disease transmission. The interaction between the incoming
monomer and the seed stabilizes the cross-b structure and thus
facilitates subsequent amyloid elongation. During the elon-
gation phase, the rate of elongation depends on the elongation
rate constant (ke), the molar concentration of the seed (amount
of free ends for fibril propagation), and the concentration of
monomer in the ‘‘amyloid-precursor state’’, which is able to
associate with the seed.
The amino acid sequence determines the three-dimen-
sional structure of a protein. It is known that differences in
the amino acid sequence of prion protein do not signifi-
cantly affect the overall protein structure (Calzolai et al.
2005; Donne et al. 1997; Gossert et al. 2005; Haire et al.
2004; Hornemann et al. 2004; Hosszu et al. 2004; Lysek
et al. 2005; Riek et al. 1996; Riek et al. 1998), but mark-
edly affect both its structural conversion from the normal
protease-sensitive form (PrP-sen) to the protease-resistant
aggregation form (PrP-res) in vitro and the interspecies
prion transmission efficiency in vivo (Kocisko et al. 1995;
Scott et al. 1989; Vanik et al. 2004; Horiuchi et al. 2000;
Priola and Chesebro 1995). In this study, we used a prion
peptide (corresponding to human PrP residues 108–144) as
a model system to examine how different amino acid
sequences influence the amyloidogenic property and
seeding efficiency. The region containing residues 108–144
of prion protein was initially predicted to contain two
putative helices H1 and H2 (Gasset et al. 1992), but the
synthetic peptide PrP (108–144) is known to form a cross-b
structure (amyloid) after incubation in solution (Chen et al.
2002; Ho et al. 2009; Liao et al. 2011; Lee and Chen 2007;
Gasset et al. 1992). When we compared the PrP (108–144)
sequence in different mammals, which may or may not be
transfected with TSE, we found sequence variations at
Fig. 1 Schematic diagram showing nucleation-dependent polymer-
ization. For a protein to form amyloid, it must be able to undergo
structural conversion to a ready-to-stack ‘‘amyloid-precursor state’’.
a Energy diagram for the two conformational states; DEn?b, denotes
the energy difference between the native state and the amyloid-
precursor state. b The process of nucleation-dependent polymeriza-
tion. kn?b is the rate constant for the structural conversion from the
native state to the amyloid-precursor state, kn is the nucleation rate
constant, and ke is the elongation rate constant. c Time course of
amyloidogenesis. For spontaneous amyloidogenesis, the slowest step
is nucleus formation. Nuclei accumulate until a critical amount is
reached that allows elongation to occur. The time before elongation
commences is called the lag time. The elongation process continues
until the concentration of protein monomer in the amyloid-precursor
state is equal to the dissociation constant for the elongation reaction
and equilibrium is reached
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position 109 (M/L), 112 (M/V), 129 (M/V/L), 135 (N/S),
138 (M/L/I), 139 (M/I), and 143(N/S) (Fig. 2). The struc-
tural and chemical properties of the amino acids M, L, V, I,
N, and S are compared in Table 1. We then synthesized
several bPrP mutant peptides to examine how amino acid
replacement affected the kinetics of fibrillogenesis and the
seeding efficiency of this peptide. Circular dichroism
spectroscopy was used in this work instead of Thioflavin T
binding assay that is commonly used in amyloid study. It is
because fluorescence intensity varies a lot among different




The prion peptides used were synthesized using the Fmoc-
polyamide method (Chen et al. 2001). The N- and C-ter-
minals of the peptides were acetylated or amidated,
respectively, to mimic the configuration and charge state in
the full-length protein. The peptides were characterized by
mass spectrometry after purification, and after lyophiliza-
tion, were stored at -30 C.
Circular dichroism spectroscopy
The peptides were dissolved at a concentration of 50 lM in
20 mM NaOAc, 140 mM NaCl (pH 3.7) and incubated in
Eppendorf tubes quiescently at 25 C for amyloid fibril
formation. At different incubation times, the samples were
placed in a 1-mm quartz cuvette and the CD spectra
between 200 and 250 nm recorded on a JASCO J-715
spectrometer (JASCO, Japan), with the bandwidth set to
2 nm and a step resolution of 0.05 nm. Two scans were
averaged for each sample and the final signal shown in the
plots was obtained from the average of several independent
repeats. To avoid contamination, a different quartz cuvette
was used for each sample, and the same cuvette was used
for the same sample for all time points. The lag time was
obtained by fitting the kinetic data using the equation:
F = A ? B/(1 ? e^(k*(t1/2 - t))), where A is the signal
during the lag phase, B the signal difference between the
lag phase and post-transition plateau, t the time, t1/2 the
time required for half-completion of the fibrillization pro-
cess, and k the rate constant of fibril growth (h-1), the lag
time being equal to t1/2–2/k for each fitted curve.
Seed titration experiments
The amyloid fibrils were spun down by centrifugation,
re-suspended in distilled water, and fragmented with 20
cycles of intermittent pulses (5 9 0.5 s; 5 s interval
between cycles) using an ultrasonic processor (UP100H,
Hielscher, USA) equipped with a 1-mm microtip at a
power setting of 40 %.
In seed titration experiments, the kinetics of fibril for-
mation were recorded by time-course measurements on a
JASCO J-715 spectrometer (JASCO, Japan). The peptide
was dissolved at a concentration of 62.5 lM in 25 mM
NaOAc and 175 mM NaCl, pH 3.7. The required volume
Fig. 2 Amino acid sequence comparison of the region corresponding
to human prion sequence 108–144 in different mammals. Human PrP
has an M/V polymorphism at position-129 and M is shown here
Table 1 Comparison of the structural and chemical properties of Met, Val, Leu, Ile, Asn, and Ser
Met Val Leu Ile Asn Ser
Branched at b-carbon - ? - ? - -
Hydrophilicitya (kcal/mol) -3.87 -0.40 -0.11 -0.24 -12.07 -7.45
Hydrophobicitya (kcal/mol) -1.41 -3.10 -3.98 -3.98 7.58 4.34
Van der Waals volumeb (A˚3) 124 105 124 124 96 73
b-sheet forming propensity expressed as the DDG (kcal/mol)c -0.46 -0.53 -0.48 -0.56 -0.38 -0.39
a-Helix-forming propensity expressed as the DDG (kcal/mol)d -0.50 -0.14 -0.62 -0.23 -0.07 -0.35
Turn potentiale 0.57 0.70 0.66 0.59 1.44 1.15
a Values are taken from Radzicka and Wolfenden (1988) and Creighton (1984)
b Values are taken from Creighton (1984)
c Values are taken from Kim and Berg (1993)
d Values are taken from O’Neil and DeGrado (1990)
e Values are taken from Hutchinson and Thornton (1994)
Effect of amino acid substitutions 787
123
of sonicated seed solution was made to a final volume of
50 lL with distilled water and added to 200 lL of the
62.6 lM peptide monomer solution to give a final mono-
mer concentration of 50 lM. The samples were placed in
1 mm quartz cuvettes and the kinetics of fibril formation
recorded every 5 s at 218 nm for 60 min. The trace over
the first 2,000 s was linearly fitted to determine the amyloid
propagation rate, and the rates in two or three independent
experiments were averaged.
Transmission electron microscopy
The samples were deposited on carbon-coated 300-mesh
copper grids and incubated for 3 min for absorption.
Negative staining was performed by staining with 2 %
uranyl acetate for 3 min. After drying, the samples were
viewed using a Hitachi H-7000 electron microscope.
Determination of the thermodynamic solubility of peptides
Different concentrations of PrP peptides (50, 10, 5, 1 lM)
were injected into a C18 column (ZORBAX Eclipse col-
umn, 4.6 mm 9 25 cm, 5 lm, Agilent, USA) by a HPLC
system (Agilent USA), then the peptides were eluted using
different acetonitrile/water mixtures containing 0.1 % tri-
fluoroacetic acid for the different peptides and detected by
UV absorption at 220 nm, then the area under the peak was
integrated to generate a standard calibration curve for each
peptide. The PrP peptides were dissolved at a concentration
of 50 lM in 20 mM NaOAc, 140 mM NaCl (pH 3.7) and
incubated at 25 C for 3 weeks for fibrillization, then the
fibril-containing samples were centrifuged for 30 min at
room temperature at 13,200g in a centrifuge (Eppendorf
5415D, USA) and the supernatant was injected into the
same column described above and the concentration of
peptide remaining in the supernatant was then determined
based on the standard calibration curve.
Results
Various PrP peptides, synthesized on a solid phase peptide
synthesizer, were dissolved in 20 mM NaOAc, 140 mM
NaCl (pH 3.7) to a final peptide concentration of 50 lM
and incubated at 25 C. Under these conditions, the pep-
tides initially formed a random coil structure, as shown
previously for the hamster peptide (Ho et al. 2009), then
gradually transformed into a b structure and associated into
amyloid fibrils during incubation, as shown by transmis-
sion electron microscopy (TEM) (Fig. 3). The cross-b
structural character of amyloid fibrils is reflected by the
negative ellipticity at 218 nm of the circular dichroism
(CD) spectrum. The time course of amyloidogenesis of the
PrP peptides with different mutations was monitored by
CD spectroscopy.
Met ? Val or Met ? Leu substitution: bPrPM109V,
bPrPM129V, bPrPM134V, and bPrPM129L
The bPrP peptide contains three methionine residues,
M109, M129, and M134, one of which, Met-134, is con-
served in all PrP sequences. Most mammalian PrPs also
have Met at residues 109 and 129, the exceptions being
mouse PrP (Leu at residue 109), dog PrP (Leu at residue
129), and human PrP (Met/Val polymorphism at residue
129). It is known that the M/V polymorphism in human PrP
markedly affects the transmission efficiency of variant
Creutzfeldt–Jakob disease (Hill et al. 1999). To examine
the effect of Met ? Val or Met ? Leu substitution on
amyloidogenesis and seeding efficiency, four single-
mutation peptides were prepared; these were bPrPM109V,
bPrPM129V, bPrPM134V, and bPrPM129L, with the
respective mutations M109 ? V, M129 ? V, M134 ?
V, and M129 ? L. The negative ellipticity at 218 nm of
the CD spectrum was used to monitor the formation of the
cross-b structure of amyloid fibrils and the CD signals were
normalized using the final signal, taken as 100 % amyloid
formation. The kinetics of amyloidogenesis for these pep-
tides are shown in Fig. 4. The lag times for these mutant
peptides were similar to that for bPrP, showing that the
Met ? Val or Leu substitutions did not affect the nucle-
ation step. bPrPM129V and bPrPM134V had slower
elongation rates (see their slopes in the elongation phase).
We surmise that the Met ? Val mutation at residue 129 or
134 might raise the kinetic conversion barrier for
bPrPM129V and bPrPM134V from the random coil state to
the amyloid-precursor state (decrease the kn?b). A slower
elongation phase has been reported in the kinetic data for
human PrP (108–144) peptide with a Met129 ? Val sub-
stitution (Liao et al. 2011), consistent with our data. A
comparison of the structural and chemical properties of
Met and Val (Table 1) shows that Val is smaller, more
hydrophobic, and has a lower helix-forming propensity and
a higher turn-forming potential than Met. We surmise that
Val at position 129 or 134 might stabilize the random coil
state of these two peptides.
The seed titration method is used to evaluate the
sequence dependency of seeding efficiency (Liao et al.
2011; Lee and Chen 2007). The kinetics of amyloidogen-
esis of samples containing the same peptide monomer
concentration and different amounts of seed solution, made
to the same final volume, were compared in the absence of
spontaneous nucleation (the lag time of spontaneous
nucleation is much longer than the observation period in
the seeding experiments). To control the quality of the
seed, homogeneous seed was prepared by ultrasonication
788 R. P.-Y. Chen
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Fig. 3 TEM images of the fibrils formed by the different bPrP-based peptides. The bars represent 100 nm
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of amyloid fibrils formed from the bPrP peptide, as
described previously (Lee and Chen 2007), and the amy-
loidogenesis initiated by seeding was monitored for 1 h by
time-resolved CD spectroscopy at 218 nm, the wavelength
giving the characteristic signal for cross-b structure for-
mation. The initial amyloid elongation rate was obtained
by linear fitting of the ellipticity data within the first
2,000 s. The minimal amount of seed required for imme-
diate amyloidogenesis was arbitrarily and empirically
determined as the lowest amount resulting in an initial
elongation rate higher than 1 9 10-4 m deg/s (the slope in
the time-resolved CD spectrum of the peptide solution
without fibril formation is always lower than 1 9 10-4 and
the slope increase is proportional to the increase in seed
amount when the slope is higher than 1 9 10-4). The
seeding efficiency was normalized as the ratio of the
minimal amount of seed required for homogeneous seeding
to that required for heterogeneous seeding ([seed]homo/
[seed]hetero). For example, the minimal percentage of bPrP
seed required to efficiently seed the same concentration of
peptides bPrP, bPrPM109V, bPrPM129V, bPrPM134V,
and bPrPM129L was 1, 1, 2, 2, and 4 %, respectively
(Fig. 5). Using the bPrP seed, the relative seeding effi-
ciencies of peptides bPrP, bPrPM109V, bPrPM129V,
bPrPM134V, and bPrPM129L were 1/1, 1/1, 1/2, 1/2, and
1/4, or 1, 1, 0.5, 0.5, and 0.25. bPrPM129L, which corre-
sponds to the dog PrP sequence, had the lowest seeding
efficiency among these peptides, suggesting that the
Met ? Leu substitution at position 129 results in a four-
fold increase in the seeding barrier. Whether a Met ? Val
substitution affects the seeding efficiency of the bPrP fibrils
or not depends on the substitution site, as only substitutions
in the C-terminal part of the peptide (M129, M134)
affected seeding efficiency. Our data are consistent with
our previous report (Lee and Chen 2007) that sequence
homology between the seed and monomer in the C-termi-
nal part of the peptide is important for seeding when res-
idue 139 of the PrP fibril seed is Ile.
One should be careful to apply the peptide results to
full-length prion protein. As mentioned in ‘‘Introduction’’,
many prion peptide segments could form amyloid fibrils,
but it is not likely that all these segments are in the amyloid
core of the amyloid fibrils formed from full-length prion
protein. Lu et al. (2007) have reported the hydrogen/deu-
terium exchange protection map of huPrP (90–231) fibrils
and showed that the region 108–144 is quite flexible
compared with the C-terminal region 168–213. Whether
the amyloidogenic region 108–144 is really involved in the
cross-b structure of the full-length prion fibrils remains to
be explored.
Val, Leu or Ile ? Met substitution: bPrPV112M,
bPrPL138M, and bPrPI139M
As shown in Fig. 2, cat, lion, human, and hamster PrPs
have Met at position 112 instead of the Val in other ani-
mals, while bank vole, mouse, and hamster and human
PrPs have Met or Ile at position-138, and other animals
have Leu at this position. Most mammal PrPs have Ile at
position 139, with the exception of hamster PrP, which has
Met at this position. The L138 ? I substitution has been
reported not to affect amyloidogenesis (Liao et al. 2011).
To compare the effects of mutating V/L/I at these positions
into M, three single-mutation peptides were prepared: these
were bPrPV112M, bPrPL138M, and bPrPI139M, contain-
ing, respectively, V112 ? M, L138 ? M, and I139 ? M.
The kinetics of amyloidogenesis of these three peptides and
bPrP peptide are compared in Fig. 6. The lag time for
bPrPI139M was about four times longer than that for bPrP,
consistent with a previous report that the mouse PrP pep-
tide, which has Ile at position 139, has a much shorter lag
time than a mouse PrP mutant peptide with the Ile 139 to M
mutation (Lee and Chen 2007). Our result supports the
conclusion that the residue at position 139 markedly affects
nucleation. Due to its b-branching property, Ile has a
higher b-sheet forming propensity than Met. We surmise
that Ile 139 might be involved in cross-b structure forma-
tion of the amyloid structure. On the other hand, Leu and
Met have a similar b-sheet forming propensity, but Leu has
a slightly higher helix-forming propensity and turn-forming
potential than Met. The lag time for bPrPL138M was sig-
nificantly shorter than that for bPrP (p \ 0.05), suggesting
that position 138, together with its neighboring residue Ile
139, are located in the cross-b structure-forming region and
that M138 favors nucleation more than L138. Surprisingly,
bPrPV112M, which corresponds to the sequence of cat PrP,
formed amyloid fibrils very rapidly and its lag time could
Fig. 4 Time course of amyloidogenesis of peptides bPrP,
bPrPM109V, bPrPM129V, bPrPM134V, and bPrPM129L monitored
by CD spectroscopy
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hardly be measured. M112 might be a key residue
responsible for the high prion susceptibility of feline
spongiform encephalopathy.
Using the bPrP seed, the relative seeding efficiencies
of peptides: bPrP, bPrPV112 M, bPrPL138M, and
bPrPI139M were 1/1, 1/1, 1/0.5, and 1/4 = 1, 1, 2, and
0.25 (Fig. 7). Although the V112 to M mutation greatly
accelerated nucleation, it did not affect seeding efficiency.
In contrast, the L138 to M mutation had less of an effect on
nucleation and increased seeding efficiency. The I139 to M
mutation decreased the seeding efficiency by fourfold,
consistent with a previous study on mouse/hamster cross-
seeding, which showed that, when fibrils derived from
mouse PrP peptide (with Ile at position-139) were used as
seed, the seeding efficiency for a mouse PrP mutant peptide
with the I139 to M mutation was fourfold lower than
homogeneous seeding (Lee and Chen 2007).
Ser ? Asn and Asn ? Ser substitution: bPrPS135N
and bPrPN143S
As shown in the sequence comparison in Fig. 2, only mule
deer and lion PrPs have Asn instead of Ser at position 135
and only pig and human PrPs have Ser instead of Asn at
position 143. Gly, Pro, Asn, and Asp are particularly
favored in turn structures. How the Asn/Ser substitution
affects the amyloidogenic behavior of the PrP peptide was
examined by studying two single-mutation peptides
bPrPS135N and bPrPN143S containing, respectively, the
S135 ? N or N143 ? S substitution. As shown in
Table 1, Asn is more hydrophilic, slightly bigger, and has a
higher turn-forming potential and lower helix-forming
propensity than Ser. The kinetics of amyloidogenesis of
bPrP peptide and peptides bPrPS135N and bPrPN143S are
Fig. 5 Seeding experiments using bPrP, bPrPM109V, bPrPM129V,
bPrPM134V, and bPrPM129L, monitored by time-resolved CD
spectroscopy. a Different amounts of bPrP seed were added to
solutions of peptides bPrP, bPrPM109V, bPrPM129V, bPrPM134V,
and bPrPM129L and the kinetics of amyloidogenesis of the mixture
monitored at 218 nm. The monomer peptide and the amount of bPrP
seed used are indicated in each panel. The fibril elongation rate was
obtained by linearly fitting the data obtained in the first 2,000 s. The
minimum amount of seed required for lag phase-free propagation is
highlighted in yellow. b Plot of initial amyloid elongation rate versus
seed amount. The threshold of 1 9 10-4 is indicated by the dashed
line. The minimal amount of bPrP seed required to efficiently seed
amyloid formation at the same concentration of peptides bPrP,
bPrPM109V, bPrPM129V, bPrPM134V, and bPrPM129L was 1, 1, 2,
2, and 4 %, respectively
Fig. 6 Time course of amyloidogenesis for bPrP, bPrPV112M,
bPrPL138M, and bPrPI139M monitored by CD spectroscopy
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compared in Fig. 8. While the S135 to N mutation did not
significantly affect the lag time, the lag time for
bPrPN143S was twice as long as that for bPrP, suggesting
that the S135 ? N mutation does not affect nucleation,
while the N143 ? S mutation does.
Using bPrP seed, the relative seeding efficiencies of
peptides: bPrP, bPrPS135N, and PrPN143S were 1/1, 1/8,
and 1/8 = 1, 0.125, and 0.125 (Fig. 9). The S135N and
N143S mutations resulted in an eightfold decrease in het-
erogeneous seeding efficiency. The amino acid sequence
for bPrPS135N is the same as that for the mule deer PrP
peptide, while that for bPrPN143S is the same as that for
the pig PrP peptide. Our data showed that the mule deer
and pig PrP peptides had the largest seeding barrier in the
bPrP seeding experiment as a result of the presence of Asn
135 in mule deer and Ser 143 in pig PrP and that the effect
of one mutation on the seeding barrier is not necessarily
related to its effect on lag time of amyloid fibril formation.
Our data also suggested that these two mutations affected
the association between the peptide monomer and the pre-
existing bPrP seed.
Other mammalian PrP peptides: lion PrP, mouse PrP,
hamster PrP, and human PrP
The data above showed that: (1) Val112 ? M accelerates
nucleation; (2) Asn143 ? Ser and Ile139 ? M retard
nucleation; and (3) Met129 ? Leu, Ser135 ? Asn,
Asn143 ? Ser, and Ile139 ? Met decrease the seeding
Fig. 7 Seeding experiments
for bPrP, bPrPV112M,
bPrPL138M, and bPrPI139M
monitored by time-resolved CD
spectroscopy. a Different
amounts of bPrP seed were
added to solutions of peptide
bPrPV112M, bPrPL138M, or
bPrPI139M and the kinetics of
amyloidogenesis of the mixture
monitored at 218 nm. The
monomer peptide and the
amount of seed used are
indicated in each panel. The
fibril elongation rate was
obtained by linearly fitting the
data from the first 2,000 s. The
minimum amount of seed
required for lag phase-free
propagation is highlighted in
yellow. b Plot of initial amyloid
elongation rate versus seed
amount. The minimal amount of
bPrP seed required to efficiently
seed amyloid formation at the
same concentration of bPrP,
bPrPV112M, bPrPL138M, and
bPrPI139M was 1, 1, 0.5, and
4 %, respectively
Fig. 8 Time course of amyloidogenesis for peptides bPrP,
bPrPS135N, and bPrPN143S monitored by CD spectroscopy
792 R. P.-Y. Chen
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efficiency of bPrP-assisted seeding experiments. As shown
in Fig. 1, some mammalian PrP sequences differ from the
bovine PrP sequence by more than one residue. Lion and
mouse PrP peptides each differ from bPrP peptide by two
residues (V112 ? M and S135 ? N for lionPrP and
M109 ? L and L138 ? M for mPrP), while hamster and
human PrP peptides each differ from bPrP peptide by three
residues (V112 ? M, L138 ? M, and I139 ? M for
haPrP and V112 ? M, L138 ? I, and N143 ? S for
huPrP). The lionPrP, mPrP, haPrP, and huPrP peptides
were synthesized and their amyloidogenic properties and
seeding efficiencies for bPrP seed were examined. As
Fig. 9 Seeding experiments for peptides bPrP, bPrPS135N, and
bPrPN143S monitored by time-resolved CD spectroscopy. a Different
amounts of bPrP seed were added to a solution of peptide bPrPV112M,
bPrPS135N, or bPrPN143S and the kinetics of amyloidogenesis of the
mixture monitored at 218 nm. The monomer peptide and the amount of
seed used are indicated in each panel. The fibril elongation rate was
obtained by linearly fitting the data for the first 2,000 s The minimum
amount of seed required for lag phase-free propagation is highlighted in
yellow. b Plot of the initial amyloid elongation rate versus seed amount.
The minimal amount of bPrP seed required to efficiently seed amyloid
formation of the same concentration of bPrP, bPrPS135N, and
bPrPN143S was 1, 8, and 8 %, respectively
Fig. 10 Time course of amyloidogenesis for peptides bPrP, lionPrP,
mPrP, haPrP, and huPrP monitored by CD spectroscopy
Fig. 11 Seeding experiments for bPrP, lionPrP, mPrP, haPrP, and
huPrP monitored by time-resolved CD spectroscopy. a Different
amounts of bPrP seed were added to a solution of peptide lionPrP,
mPrP, haPrP, or huPrP and the kinetics of amyloidogenesis of the
mixture monitored at 218 nm. The monomer peptide and the amount
of seed used are indicated in each panel. The fibril elongation rate
was obtained by linearly fitting the data for the first 2,000 s. The
minimum amount of seed required for lag phase-free propagation is
highlighted in yellow. b Plot of the initial amyloid elongation rate
versus seed amount. The minimal amount of bPrP seed required to
efficiently seed amyloid formation at the same concentration of bPrP,
lionPrP, mPrP, haPrP, and huPrP was 1, 2, 0.5, 2, 2 %, respectively
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shown in Fig. 10, of these four peptides, only haPrP had a
lag time longer than bPrP. As described above, Met 112 is
one of the residues promoting amyloid formation and Met
139 one of the residues retarding amyloid formation, and
since haPrP has both residues, its lag time of 118.9 h is not
as long as that of the bPrPI139M peptide (214.9 h). Sim-
ilarly, although the N143S substitution has a retardation
effect on nucleation, the retardation effect was neutralized
by the presence of the V112M substitution in the case of
huPrP.
Using bPrP seed, the relative seeding efficiencies of
peptides: bPrP, lionPrP, mPrP, haPrP, and huPrP were 1/1,
1/2, 1/0.5, 1/2, and 1/2 = 1, 0.5, 2, 0.5, and 0.5 (Fig. 11).
LionPrP, haPrP, and huPrP had only a slightly lower
seeding efficiency than homogeneous seeding.
The amyloidogenic properties of all the PrP peptides
used in this study are compared in Table 2. According to
the results of single substitutions described above, L138M
substitution improves seeding efficiency and S135N,
N143S, M129L, and I139M decrease seeding efficiency.
When the substitutions of these two groups are present in
the same peptide, they tend to cancel each other out. For
example, bPrPI139M had a fourfold lower seeding effi-
ciency, and bPrPL138M a twofold higher seeding effi-
ciency, than bPrP homogeneous seeding, but when both
substitutions were present in the same peptide (haPrP), the
seeding efficiency was only twofold lower than that for
bPrP homogeneous seeding.
Thermodynamic solubility of the PrP peptides
The PrP peptides used in this study had good solubility in
acidic buffer. CD spectroscopy showed that they were in a
random coil state. In the structural ensemble, a small por-
tion of the peptides is in the less stable ‘‘amyloid-precursor
state’’ and, during prolonged incubation, the molecules in
the ‘‘amyloid-precursor state’’ gradually associate and form
a stable aggregation form, called nuclei. The nuclei asso-
ciate with other molecules in the ‘‘amyloid-precursor state’’
one-dimensionally and finally form amyloid fibrils. The
concentration of the peptide remaining in solution, also
called the critical concentration, is used to represent the
thermodynamic solubility of the peptide. The PrP peptides
were dissolved at a concentration of 50 lM in 20 mM
NaOAc, 140 mM NaCl (pH 3.7) and incubated at 25 C for
3 weeks, then the fibrils in the solution were spun down
and the concentration of peptide remaining in the super-
natant determined by high-pressure liquid chromatography
(HPLC). The thermodynamic solubility results are shown
in Fig. 12 and are compared with the properties detailed in
Table 2 Comparison of the amyloidogenic properties of the PrP peptides used in this study





bPrP fibrils as seeds
bPrP 61.1 ± 10 1.95 ± 0.33 1
One residue difference
catPrP/bPrPV112M ND 1.65 ± 0.11 1
dogPrP/bPrPM129L 71.4 ± 12 1.19 ± 0.07*** 0.25
bvPrP/bPrPL138M 42.3 ± 13.5* 1.39 ± 0.01** 2
mdPrP/bPrPS135N 72.2 ± 5.5 1.62 ± 0.24 0.125
pigPrP/bPrPN143S 117.8 ± 1.5*** 2.79 ± 0.23*** 0.125
bPrPM109V 83.3 ± 14.9 1.72 ± 0.06 1
bPrPM129V 57.9 ± 26.3 2.71 ± 0.03*** 0.5
bPrPM134V 55.2 ± 13.6 3.29 ± 0.13*** 0.5
bPrPI139M 214.9 ± 23.9*** 3.25 ± 0.21*** 0.25
Two residue difference
lionPrP (V112M, S135N) 51.2 ± 14.3 1.63 ± 0.06 0.5
mPrP (M109L, L138M) 65.5 ± 6.8 1.09 ± 0.02*** 2
Three residue difference
haPrP (V112M, L138M, I139M) 118.9 ± 4.9*** 2.95 ± 0.59*** 0.5
huPrP (V112M, L138I, N143S) 61.8 ± 8.4 1.16 ± 0.07*** 0.5
For peptides having only one residue different from bPrP, the bPrP-based name is also provided. For peptides with more than one residue
different from bPrP, the substitutions are shown in parenthesis
bPrP bovine PrP, bvPrP bank vole PrP, mdPrP mule deer PrP, mPrP mouse PrP, haPrP hamster PrP, huPrP human PrP with Met at residue-129,
ND not detectable
* p \ 0.05; ** p \ 0.01; *** p \ 0.001 compared to bPrP
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Table 2. Met is more hydrophilic than Val, Ile, and Leu,
while Asn is more hydrophilic than Ser. Although the
I139 ? M substitution indeed increased the thermody-
namic solubility of the peptide (bPrPI139M and haPrP),
our results showed that the thermodynamic solubility of the
peptide was not proportional to the sum of the hydrophi-
licity of its amino acid composition. For example, a com-
parison of bPrP and mPrP with exactly the same amino
acid composition showed that their thermodynamic solu-
bilities were significantly different. Moreover, thermody-
namic solubility did not correlate with lag time or seeding
efficiency.
Conclusions
Amyloid formation is a special kind of protein aggregation,
in which a special conformer (amyloid-precursor state)
stacks regularly and the stacked aggregate promotes further
association. During evolution, amino acid residues in
mammalian prion peptides have mutated to others with
similar chemical properties, with hydrophobic residues
mutating to another hydrophobic residue (V, L, I, M) and
hydrophilic residues mutating to another hydrophilic resi-
due (N, S). However, some amino acid differences, such as
V112M, N143S, and I139M, in prion peptides affect the
population of the amyloid-precursor state and thus affect
nucleation. Based on our results, we conclude that Met112
is an amyloid formation-promoting residue, while Ser143
and Met139 are amyloid formation-retarding residues.
Moreover, the effect of one mutation on amyloidogenesis
does not correlate with its effect on the seeding barrier.
Using bPrP fibrils for seeding, the S135N (mule deer PrP)
and N143S (pig PrP) mutations led to the lowest hetero-
geneous seeding efficiency (8-fold decrease) and the
M129L (dog PrP) and I139M mutations led to a fourfold
decrease in seeding efficiency, but interestingly, L138M
(bank vole PrP) slightly increased seeding efficiency.
Finally, when residues with opposite effects are present in
the same peptide, their effects tend to cancel each other
out.
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